Skip to main content

Day: May 9, 2024

Innospec Reports First Quarter 2024 Financial Results

Strong contribution from Performance Chemicals drives operating income growth of 23 percent $80.6 million cash generated from operations; Net cash improves to $270.1 million Dividend increased by 10 percent; Strong debt-free balance sheet GAAP EPS of $1.65 and adjusted non-GAAP EPS of $1.75 ENGLEWOOD, Colo., May 09, 2024 (GLOBE NEWSWIRE) — Innospec Inc. (NASDAQ: IOSP) today announced its financial results for the first quarter ended March 31, 2024. The Company declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10 percent. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024. Total revenues for the first quarter were $500.2 million, a decrease of 2 percent from $509.6 million in the corresponding period last year. Net income...

Continue reading

Quisitive Sets First Quarter 2024 Earnings Call for Wednesday, May 22, 2024 at 5:00 p.m. ET

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — Quisitive Technology Solutions, Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX: QUISF), a premier Microsoft Cloud and AI solutions provider, will hold a conference call on Wednesday, May 22nd at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss its financial results for the first quarter ended March 31, 2024. Financial results will be issued in a press release prior to the call. Quisitive management will host the earnings call, followed by a question and answer period. Date: Wednesday, May 22, 2024Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time) Webcast Link: HereToll Free dial-in: 1-877-704-4453International dial-in: 1-201-389-0920 Please call the conference telephone number 10 minutes prior to the start time. An operator will register your name and organization. If...

Continue reading

U.S. Energy Corp. Reports Financial and Operating Results for First Quarter 2024

HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing oil and natural gas assets, today reported financial and operating results for the three months ended March 31, 2024.  FIRST QUARTER 2024 HIGHLIGHTSNet daily production of 1,207 barrels of oil equivalent per day (“Boe/d”); Oil production of 68,599 barrels, or 62% of total production; Lease Operating Expense of $3.2 million, or $29.02 per Boe, a 28% and 2% decrease, respectively, from first quarter of 2023; Adjusted EBITDA of $0.2 million; Repurchased approximately 0.3 million shares of common stock, representing nearly 1.5% of outstanding shares, for approximately $0.3 million; Ended the quarter with an outstanding debt balance...

Continue reading

Sachem Capital Sets Dates for First Quarter 2024 Earnings Release and Conference Call

BRANFORD, Conn., May 09, 2024 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) (the “Company”) announced today that the Company will release its first quarter 2024 financial results before market open on Friday, May 10, 2024. A webcast and conference call to discuss the results will be held on Friday, May 10, 2024, at 8:00 a.m. Eastern Time. Webcast:A webcast of the conference call will be available on the Investors section of the Company’s website www.sachemcapitalcorp.com. To listen to the live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register and install any necessary audio software. To Participate in the Telephone Conference Call:Dial in at least 15 minutes prior to the start time. Domestic: 1-844-825-9789International: 1-412-317-5180 Conference Call Playback:Domestic:...

Continue reading

BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024

MISSISSAUGA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on Thursday, May 16, 2024 after market hours. A presentation on the Company’s first quarter 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals...

Continue reading

Conifex Announces First Quarter 2024 Results

VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”, “we” or “us”) (TSX: CFF) today reported results for the first quarter ended March 31, 2024.  EBITDA* was negative $0.5 million for the quarter compared to EBITDA of negative $3.5 million in the fourth quarter of 2023 and negative $6.9 million in the first quarter of 2023. The first quarter results were favourably impacted by $3.0 million insurance settlement for the loss of the Osilinka Logging Camp. Net loss was $4.5 million or $0.11 per share for the quarter versus net loss of $5.3 million or $0.14 per share in the previous quarter and net loss of $8.1 million or $0.20 per share for the year-earlier quarter. Selected Financial Highlights The following table summarizes our selected financial information for the comparative periods. The...

Continue reading

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP Reported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual Meeting Published positive data from the Phase 1 Trial of TPST-1120 in patients with advanced solid tumors in the Journal of Cancer Research Communications Presented new data at the SITC 2024 Spring Scientific Meeting elucidating the mechanism of TPST-1120 and supporting its potential in multiple cancersBRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update. “The positive data...

Continue reading

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.   “Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients,” said Thomas Zindrick, President, Chairman and CEO of Genelux. “Looking ahead, we are excited about advancing Olvi-Vec into additional cancer indications through intravenous administration, a physician-preferred route of delivery, and seeking to further validate our hypothesis that Olvi-Vec may reverse resistance to platinum in multiple tumor types.” The Company expects to initiate our Phase 2 trial in recurrent non-small cell lung cancer in the second quarter...

Continue reading

AMN Healthcare Announces First Quarter 2024 Results

Quarterly revenue of $821 million; GAAP EPS of $0.45 and adjusted EPS of $0.97 DALLAS, May 09, 2024 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2024 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q1 2024 % Change Q1 2023Revenue $820.9 (27%)  Gross profit $257.5 (30%)  Net income $17.3 (79%)  GAAP diluted EPS $0.45 (78%)  Adjusted diluted EPS* $0.97 (61%)  Adjusted EBITDA* $97.7 (46%)  * See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Non-GAAP Reconciliation Tables” for a reconciliation of non-GAAP items. Business HighlightsFirst quarter revenue...

Continue reading

VALHI REPORTS FIRST QUARTER 2024 RESULTS

Dallas, Texas, May 09, 2024 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) reported net income attributable to Valhi stockholders of $7.8 million, or $.27 per share, in the first quarter of 2024 compared to a net loss attributable to Valhi stockholders of $4.9 million, or $.17 per share, in the first quarter of 2023. Net income attributable to Valhi stockholders increased in the first quarter of 2024 as compared to the first quarter of 2023 primarily due to higher operating income from our Chemicals Segment partially offset by lower operating income from our Component Products Segment and our Real Estate Management and Development Segment. The Chemicals Segment’s net sales of $478.8 million in the first quarter of 2024 were $52.5 million, or 12%, higher than in the first quarter of 2023. The Chemicals Segment’s net sales increased...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.